Ayesha Al-Sabah

Ayesha Al-Sabah

Auto-generated profile, based on publicly available information

Ayesha Al-Sabah

Reconstructive Surgery & Regenerative Medicine Group (ReconRegen), Institute of Life Sciences, Swansea University Medical School, Swansea, SA2 8PP, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2017 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
SKStuart Kyle
Stuart Kyle
ZJZita M. Jessop
Zita M. Jessop
AAAyesha Al‐Sabah
Ayesha Al‐Sabah
IWIain S. Whitaker
Iain S. Whitaker

1 May 2018 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
STSam Tarassoli
Sam Tarassoli
ZJZita M. Jessop
Zita M. Jessop
AAAyesha Al-Sabah
Ayesha Al-Sabah
NGNeng Gao
Neng Gao
SWSairan Whitaker
Sairan Whitaker
IWIain S. Whitaker
Iain S. Whitaker

8 July 2019 in Biofabrication
Verified
Journal Article
Open access
ZJZita M Jessop
Zita M Jessop
AAAyesha Al-Sabah
Ayesha Al-Sabah
NGNeng Gao
Neng Gao
SKStuart Kyle
Stuart Kyle
BTBethan Thomas
Bethan Thomas
IWIain S Whitaker
Iain S Whitaker
One of the main challenges for extrusion 3D bioprinting is the identification of non-synthetic bioinks with suitable rheological properties and biocompatibility. Our aim was to optimize and compare the printability of crystal, fibril and blend formulations of novel pulp derived nanocellulose bioinks and assess biocompatibility with human nasoseptal chondrocytes. The printability of crystalline, fibrillated and blend formulations of nanocellulose was determined by assessing resolution (grid-line assay), post-printing shape fidelity and rheology (elasticity, viscosity and shear thinning characteristics) and compared these to pure alginate bioinks. The optimized nanocellulose-alginate bioink was bioprinted with human nasoseptal chondrocytes to determine cytotoxicity, metabolic activity and bioprinted construct topography. All nanocellulose-alginate bioink combinations demonstrated a high degree of shear thinning with reversible stress softening behavior which contributed to post-printing shape fidelity. The unique blend of crystal and fibril nanocellulose bioink exhibited nano- as well as micro-roughness for cellular survival and differentiation, as well as maintaining the most stable construct volume in culture. Human nasoseptal chondrocytes demonstrated high metabolic activity post printing and adopted a rounded chondrogenic phenotype after prolonged culture. This study highlights the favorable rheological, swelling and biocompatibility properties of nanocellulose-alginate bioinks for extrusion-based bioprinting.

1 September 2017 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
ZJZita M. Jessop
Zita M. Jessop
AAAyesha Al-Sabah
Ayesha Al-Sabah
MGMatthew D. Gardiner
Matthew D. Gardiner
ECEmman Combellack
Emman Combellack
KHKarl Hawkins
Karl Hawkins
IWIain S. Whitaker
Iain S. Whitaker

1 May 2019 in Carbohydrate Polymers
Verified
Journal Article
Closed access
AAAyesha Al-Sabah
Ayesha Al-Sabah
SBStephanie E A Burnell
Stephanie E A Burnell
ISIrina N. Simoes
Irina N. Simoes
ZJZita Jessop
Zita Jessop
NBNafiseh Badiei
Nafiseh Badiei
IWIain S. Whitaker
Iain S. Whitaker

23 February 2017 in Frontiers in Surgery
Verified
Journal Article
Open access
SASarah Al-Himdani
Sarah Al-Himdani
ZJZita M. Jessop
Zita M. Jessop
AAAyesha Al-Sabah
Ayesha Al-Sabah
ECEmman Combellack
Emman Combellack
AIAmel Ibrahim
Amel Ibrahim
IWIain S. Whitaker
Iain S. Whitaker
Recent advances in microsurgery, imaging and transplantation have led to significant refinements in autologous reconstructive options, however the morbidity of donor sites remains. This would be eliminated by successful clinical translation of tissue-engineered solutions into surgical practice. Plastic surgeons are uniquely placed to be intrinsically involved in the research and development of laboratory engineered tissues and their subsequent use. In this article we present an overview of the field of tissue engineering, with the practicing plastic surgeon in mind. The Medical Research Council (MRC) states that regenerative medicine and tissue engineering “holds the promise of revolutionising patient care in the twenty-first century”. The UK government highlighted regenerative medicine as one of the key eight great technologies in their industrial strategy worthy of significant investment. The long-term aim of successful biomanufacture to repair composite defects depends on interdisciplinary collaboration between cell biologists, material scientists, engineers and associated medical specialties, however currently there is a current lack of coordination in the field as a whole. Barriers to translation are deep rooted at the basic science level, manifested by a lack of consensus on the ideal cell source, scaffold, molecular cues and environment and manufacturing strategy. There is also insufficient understanding of the long-term safety and durability of tissue-engineered constructs. This review aims to highlight that individualised approaches to the field are not adequate and research collaboratives will be essential to bring together differing areas of expertise to expedite future clinical translation. The use of tissue engineering in reconstructive surgery would result in a paradigm shift but it is important to maintain realistic expectations. It is generally accepted that it takes 20–30 years from the start of basic science research to clinical utility, demonstrated by contemporary treatments such as bone marrow transplantation. Although great advances have been made in the tissue engineering field, we highlight the barriers that need to be overcome before we see the routine use of tissue engineered solutions.